Some stroke patients in Prince Edward Island are set to participate in a worldwide research initiative focused on enhancing stroke outcomes by optimizing the use of a blood-clot-dissolving medication in emergency scenarios. Health P.E.I. is playing a role in this study to determine the most efficient dosage of Tenecteplase, a medication already in use on the island.
Dr. Heather Williams, a neurologist and head of Health P.E.I.’s stroke steering committee, stated, “We are investigating whether a reduced dosage of this drug can maintain its efficacy in breaking down blood clots and saving stroke-affected brains.” Patients for the study will be recruited through emergency departments.
“If a stroke patient is eligible for clot-dissolving treatment, emergency physicians will assess their suitability for the trial,” Dr. Williams explained. “Those eligible will promptly receive this potentially life-saving intervention, with discussions about research participation following the initial emergency care phase.”
The study will also explore the medication’s effectiveness for patients on blood thinners and its potential synergies with a neuroprotective drug known as NoNO-42 to prevent brain cell damage during strokes. Dr. Williams highlighted the role of NoNO-42 in reducing brain toxins released during stroke events, aiming to preserve brain cell integrity until normal blood flow is restored.
Notably, NoNO-42 has connections to Prince Edward Island, where UPEI scientists contributed to its development. Dr. Andrew Tasker, a neuropharmacology professor at UPEI’s Atlantic Veterinary College, expressed pride in the drug’s progress and its potential benefits for stroke patients and their families.
While NoNO-42 remains in the trial phase, Tasker remains optimistic about its impact, stating, “Although not a complete remedy, it could save lives and enhance post-stroke functional independence.” Dr. Williams shares this optimism, envisioning improved stroke outcomes leading to decreased disability, nursing home admissions, and stroke-related mortality.
Approximately 15% of stroke patients in P.E.I. are eligible for Tenecteplase treatment, automatically enrolling them in the upcoming study. The trial is scheduled to commence in the autumn, spanning 12 to 18 months, with data analysis and publication expected within the subsequent two years.